Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 22 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

45%

10 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

5 recruiting

Enrollment Performance

Analytics

Phase 3
10(58.8%)
Phase 2
4(23.5%)
N/A
2(11.8%)
Phase 1
1(5.9%)
17Total
Phase 3(10)
Phase 2(4)
N/A(2)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (22)

Showing 20 of 22 trials
NCT07154316Phase 2Recruiting

Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer

Role: collaborator

NCT07025850Phase 1Not Yet Recruiting

Efficacy Study of Digoxin Combined With Serplulimab and Chemotherapy in First-Line Treatment of MSS Advanced Colorectal Cancer

Role: collaborator

NCT06863831Not ApplicableEnrolling By Invitation

A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC

Role: collaborator

NCT02972372Not ApplicableRecruiting

Chemoradiation Versus Esophagectomy for Locally Advanced Esophageal Cancer

Role: collaborator

NCT06086457Phase 3Recruiting

PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer

Role: collaborator

NCT06084897Phase 2Recruiting

Radiotherapy in Patients With Metastatic Esophageal Cancer Responding to PD-1 Inhibitor Plus Chemotherapy

Role: collaborator

NCT06301386Phase 2Not Yet Recruiting

Everolimus Combined With PD-1 in Advanced Colorectal Cancer Patients

Role: collaborator

NCT05244798Phase 3Not Yet Recruiting

Sintilimab Plus NCT or NCRT Versus NCRT for ESCC

Role: collaborator

NCT05443672Unknown

Multi-center Study of Deep Learning AI in Breast Mass

Role: collaborator

NCT04966611Unknown

Anlotinib for Esophageal Cancer (AFEC)

Role: lead

NCT03070262Phase 3Unknown

The Efficacy and Safety of Caffeic Acid for Esophageal Cancer

Role: collaborator

NCT02979691Phase 2Completed

Phase II/III Study Comparing Chemoradiotherapy With Radiotherapy in Elderly Patients With Esophageal or Esophagogastric Cancer - 3JECROG P-01

Role: collaborator

NCT03950518Phase 3Unknown

Novel Treatment of Advanced Hepatocellular Carcinoma

Role: collaborator

NCT03940378Phase 3Unknown

Treatment of Advanced Intrahepatic Cholangiocarcinoma

Role: collaborator

NCT03308552Phase 3Unknown

Radiotherapy With or Without Concurrent Chemotherapy for Limited Lymphatic Metastasis of Esophageal Cancer - 3JECROG P-02

Role: collaborator

NCT03298204Completed

Definitive (Chemo)Radiotherapy for Patients With Esophageal Cancer - 3JECROG R-01

Role: collaborator

NCT03731442Phase 3Recruiting

Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients

Role: collaborator

NCT03286920Unknown

Effect of Postoperative Family Nutrition Mode on Weight/BMI of Patients With Esophageal Cancer

Role: collaborator

NCT03274427Phase 3Unknown

Treatment of Intermediate-stage Hepatocellular Carcinoma

Role: collaborator

NCT03278444Phase 3Unknown

Treatment of Advanced Hepatocellular Carcinoma

Role: collaborator